VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 128 filers reported holding VERVE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,783,188 | -29.3% | 1,416,530 | 0.0% | 0.11% | -29.9% |
| Q2 2023 | $26,559,938 | +30.0% | 1,416,530 | 0.0% | 0.15% | +38.7% |
| Q1 2023 | $20,426,363 | -25.5% | 1,416,530 | 0.0% | 0.11% | -32.7% |
| Q4 2022 | $27,409,856 | -43.7% | 1,416,530 | 0.0% | 0.16% | -48.3% |
| Q3 2022 | $48,658,000 | +124.8% | 1,416,530 | 0.0% | 0.32% | +159.3% |
| Q2 2022 | $21,645,000 | -33.0% | 1,416,530 | 0.0% | 0.12% | -33.9% |
| Q1 2022 | $32,325,000 | -38.1% | 1,416,530 | 0.0% | 0.19% | -26.8% |
| Q4 2021 | $52,227,000 | -21.6% | 1,416,530 | 0.0% | 0.25% | -13.0% |
| Q3 2021 | $66,577,000 | -22.0% | 1,416,530 | 0.0% | 0.29% | -22.1% |
| Q2 2021 | $85,346,000 | – | 1,416,530 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $28,967,026 | 13.98% |
| Alphabet Inc. | 10,549,086 | $152,117,820 | 8.44% |
| MPM BioImpact LLC | 803,501 | $11,586,484 | 3.01% |
| Casdin Capital, LLC | 2,120,571 | $30,578,634 | 2.52% |
| Novo Holdings A/S | 1,200,000 | $17,304,000 | 1.14% |
| Redmile Group, LLC | 1,120,679 | $16,160,191 | 0.70% |
| Avidity Partners Management LP | 1,351,700 | $19,491,514 | 0.65% |
| ARK Investment Management | 4,482,091 | $64,631,752 | 0.44% |
| BVF INC/IL | 650,000 | $9,373,000 | 0.34% |
| Cormorant Asset Management, LP | 350,000 | $5,047 | 0.33% |